Menu

Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

info@newloxgold.com

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory


Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


13. November 2020 | 12:40 CET

Pfizer, BioNTech, Desert Gold - inoculate portfolios with gold!

  • Gold
Photo credits: pixabay.com

After only three days, disillusionment already! The winners of yesterday are the losers of today. Since Monday's vaccination rocket, the markets have been hanging around up there, looking to see if any more buyers have left the sickbed of the last bear market. Unfortunately, no, the case is rather that airlines are, on average, down 5% again and a battered TUI is looking for further state aid which pushes the price back towards 4 euros. The problematic week began as the Dow rose by 4% to a new record high, and yields on ten-year government bonds shot up by almost 17% in a single day as investors relinquished security. Oil prices rose by 8% as people now believe that the stalled economy is coming back to life.

Meanwhile, the US dollar index rose by about 60 basis points, while even some exotic currencies with higher beta jumped too. Of course, some gold and silver enthusiasts wonder if a vaccine is enough to kill both the Covid-19 virus and the bull market in precious metals as gold and silver lost between 5 and 9%. However, if you look at the markets today, the chances are that smart money, in particular, will start to buy the dips in the precious metals.

time to read: 4 minutes by André Will-Laudien


Jared Scharf, CEO, Desert Gold Ventures Inc.
"[...] Our SMSZ project is the largest contiguous land package of any exploration company in the region at 400km2 and overlays a 38km portion of the prolific Senegal Mali Shear Zone. [...]" Jared Scharf, CEO, Desert Gold Ventures Inc.

Full interview

 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


Pfizer - Sell on good news

Pfizer and BioNTech announced on November 9, 2020, that their mRNA-based vaccine candidate BNT162b2 against COVID-19 had demonstrated significant efficacy against CORONA in participants without prior evidence of SARS-CoV-2 infection. This was based on the first interim analysis of effectiveness, which was performed on November 8, 2020, by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical trial. The DMC reviewed a total of 94 cases. Case allocation between vaccinated individuals and those receiving the placebo showed a vaccine efficacy rate of over 90%, seven days after the second dose. This means that protection can be achieved 28 days after the start of vaccination, which consists of a 2-dose regimen. This is a real breakthrough in the pandemic and has significantly improved the image of the pharmaceutical industry almost overnight. So far, so good.

However, Pfizer's CEO immediately took advantage of the high share price to sell shares in the Company worth USD 5.6 million. The information about the sale is contained in documents submitted to the US Securities and Exchange Commission (SEC). The media reported very luridly on the subject, but we congratulate Mr Albert Bourla on this good portfolio decision. One sells shares when they are high - CHAPEAU!

The Pfizer share opened at USD 41.94 on Monday morning after the announcement, up 15% from the close of trading on Friday. Since then, the shares have fallen back to USD 37.7. Pfizer's market capitalization is now an impressive USD 212 billion, and the stock is trading near its 10-year high - investors should do the same as the CEO.

BioNTech - Higher, faster, further

Pfizer, the established blockbuster manufacturer, and German junior Company BioNTech SE announced that they have entered into an agreement with the European Commission to supply 200 million doses of their vaccine candidate (BNT162b2) against Covid-19 to the member states of the European Union (EU) with the option to supply an additional 100 million doses. Subject to clinical success and regulatory approval, mass vaccination is expected to begin as early as the end of 2020. That sounds hopeful!

The vaccine doses for Europe will be produced in BioNTech's German production facilities and Pfizer's in Belgium. If the vaccine in question is approved by the European Medicines Agency (EMA), the preparations will be distributed according to the EU distribution key. Namely, to the notified reference countries that have chosen to receive the vaccine under this agreement. BioNTech itself has hardly any products on the market so far but is also very active in cancer research. A unique feature of the corona vaccine is that it has to be cooled at a temperature of at least minus 70 degrees Celsius from production to administration, which still represents a global logistical challenge for corresponding ultra-cool transports. In such cases, we can think of a standard DAX stock: The Linde Group with its industrial gases - this is a strategy that few people have in mind.

As far as BioNTech is concerned, the valuation of the Company's market capitalization shot up from USD 14 billion to USD 27 billion in just 6 weeks, to a price of over USD 110 billion. Interestingly, of the known issuers, there are almost only LONG derivatives on this value if this is not an excellent sign for the exit.

Desert Gold - Rapunzel from the desert

Far from the effectiveness of essential vaccines, there are other exciting supplements for the depot. Because if all that we have heard in the last five days should not happen as positively as the mass of investors probably currently suspects, the gold and silver sector will come out of obscurity again. Yesterday the yellow metal climbed once again to over USD 1,880. Silver is following suit and platinum is also involved this time.

No longer so unknown, Desert Gold Ventures Inc., is a commodity explorer in search of gold in Mali (Africa). The Company's flagship project is the Senegal Mali Shear Zone project, which covers 410 square kilometres in western Mali. The Company for example acquired stakes in the Sebessounkoto Sud and Djelimangara gold projects in western Mali. These are vast areas of land with great potential, as the district is known for its extensive mineral deposits. The Company is involved in the Byumba exploration permits north of Rwanda's capital Kigali, the Djimbala project and the Farabantourou and Segala Ouest projects in Mali. If a larger deposit is discovered in the current drilling operations, Desert Gold could be an exciting takeover target for the re-strengthened majors in the gold industry. Barrick is also looking for further projects in Africa, as production costs are on average 25% lower than in the other commodity continents. For a commodities Company, the valuation of Desert at CAD 20 million is only the blink of an eye in the long balance sheet.

The Desert share currently tends to be highly volatile and is anything but boring. From the end of July to October 2020, for example, it was almost in third place. Since then, it has risen again by more than 50%, with a significant increase in turnover. Anyone who waits here lethargically for the vaccine will overhear the bell for a new start!


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

26. November 2020 | 11:36 CET | by Nico Popp

Osino Resources, Barrick Gold, Newmont: So are the doublers in Africa?

  • Gold

When it comes to growth, professional investors look to Africa as well as Asia. In 2018 Rwanda and Guinea were the world's fastest-growing economies: the economies of both countries grew by 8.6%. Even countries like Benin, Ethiopia, Gambia or Burkina Faso are still among the top 20 in the world. But what is the reason for high growth in Africa anyway? In addition to a young and rapidly growing population, which drives the domestic market, education from a level of training is also an essential factor. Only in this way can emerging economies also participate in more complex value creation. Legal security and stability are also important factors when foreign investors look to Africa. One country that is considered highly developed and legally secure within Africa is Namibia.

Read

19. November 2020 | 09:27 CET | by Nico Popp

AngloGold Ashanti, Blackrock Gold, Newmont: Investing in gold - but how?

  • Gold

Gold investors are in a comfortable situation: The precious metal has lost a little from its highs, but still shows excellent relative strength at the USD 1,900 an ounce mark. Although news of vaccines has taken some pressure off the markets in the short term, the big picture for gold investors remains intact. The crisis of the century requires trillion-dollar measures. This flood of money, in turn, increases the risk of further problems and could drive inflation. Contrary to the opinion of many investors, it is not inflation that drives the gold price, but their expectations. Given the measures already taken and those still in the pipeline by governments and central banks, there is every reason for increased inflationary expectations. But how does an investment in the expected gold boom succeed?

While grandmother still hid bars and coins under the bed, today's investors can resort to gold ETCs. These usually securitize physical gold and can also be held in custody at attractive fees and actively traded. Yield hunters nevertheless prefer to use gold shares. The reason: stocks such as AngloGold Ashanti, Blackrock Gold or Newmont usually offer leverage on the gold price. Depending on how a Company develops, the gold reserves in the ground are also valued.

Read

16. November 2020 | 09:48 CET | by André Will-Laudien

Velocity Minerals, B2Gold, Delivery Hero: We take up the fight!

  • Gold

The news of a vaccine against Corona with a success rate of 90% caused markets to skyrocket since last Monday. While the Dow Jones and the S&P set 500 new records, gold plummeted by as much as USD 118 in one day. Gold's most significant daily drop in more than seven years also wiped out its breakout from a 3-month downward wedge last Friday.

As gold futures closed below USD 1,890 this week on the Comex, the strong sell-off below this support brings with it the possibility that the zone between USD 1,750 and USD 1,800 will be tested again before the correction of the safe-haven metal's large gains finds a significant bottom. The gold futures base of USD 1,800 has technically become a critical support level, an area that dates back to the bull market of 2008.

Read